Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Corline Biomedical ABFRA:IZ7 -2.52%43 Interest Coverage is No Debt (1) as of Mar. 2026, which is 100% below its 10-year median of 10,000.00. GuruFocus rates FRA:IZ7 with a GF Score™ of 43/100 and a GF Value™ of €0.45. The stock has 3 warning signs investors should review. Among 376 Biotechnology companies, Corline Biomedical AB ranks worse than 265957.18% on this metric.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's
Operating Income
by its Interest Expense. Corline Biomedical AB's
Operating Income
for the
three
months ended in Mar. 2026 was €-0.23 Mil. Corline Biomedical AB's Interest Expense for the
three
months ended in Mar. 2026 was €0.00 Mil.
Corline Biomedical AB has no debt.
The higher the ratio, the stronger the company's financial strength is.
(1) Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
The historical rank and industry rank for Corline Biomedical AB's Interest Coverage or its related term are showing as below:
FRA:IZ7's Interest Coverage is not ranked *
in the Biotechnology industry.
Industry Median: 104.025 * Ranked among companies with meaningful Interest Coverage only.
Corline Biomedical AB (FRA:IZ7) Interest Coverage Explanation
Ben Graham requires that a company has a minimum interest coverage of 5 with the companies he invested. If the interest coverage is less than 2, the company is burdened by debt. Any business slow or recession may drag the company into a situation where it cannot pay the interest on its debt.
Interest Coverage is an important factor when GuruFocus ranks a company's overage Financial Strength .
Corline Biomedical AB Interest Coverage Related Terms
Corline Biomedical AB Interest Coverage Historical Data
* Premium members only.
The historical data trend for Corline Biomedical AB's Interest Coverage can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Note: For Interest Coverage, "No debt" indicates no long-term debt. An indication of "No Debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.
FRA:IZ7 vs VRTX, REGN, ALNY: Interest Coverage Comparison
For the Biotechnology subindustry, Corline Biomedical AB's Interest Coverage, along with its competitors' market caps and Interest Coverage data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corline Biomedical AB Interest Coverage vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corline Biomedical AB's Interest Coverage distribution charts can be found below:
* The bar in red indicates where Corline Biomedical AB's Interest Coverage falls into.
Corline Biomedical AB Interest Coverage Calculation
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Interest Coverage of No Debt <sup>(1)</sup> mean?
Corline Biomedical AB (FRA:IZ7) has a Interest Coverage of No Debt (1) as of Mar. 2026. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Corline Biomedical AB and its competitors. This is 100% below median its historical median of 10,000.00. According to the industry distribution chart, Corline Biomedical AB ranks #999999 out of 376 companies in the Biotechnology industry.
Is Corline Biomedical AB's Interest Coverage too high?
Corline Biomedical AB's current Interest Coverage of No Debt (1) is 100% below median its 10-year median of 10,000.00. Based on the distribution chart, Corline Biomedical AB ranks #999999 out of 376 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Corline Biomedical AB has a GF Score™ of 43/100, reflecting its overall financial health beyond just this single metric.
How does Corline Biomedical AB's Interest Coverage compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Corline Biomedical AB ranks #999999 out of 376 companies for Interest Coverage. This places Corline Biomedical AB in the lower half of its industry. The industry median Interest Coverage is 104.03. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Coverage for a Biotechnology company?
The median Interest Coverage among Biotechnology companies is 104.03, based on 376 companies in the industry. Companies in the top quartile (top 25%) have a Interest Coverage significantly above this median, while those in the bottom quartile fall well below. However, Interest Coverage should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Coverage mean?
A high Interest Coverage can signal that a stock is expensive relative to its fundamentals. Interest Coverage measures a company's capability to pay interest expenses on its debt. View historical data on Corline Biomedical AB and its competitors. For the Biotechnology industry, the median Interest Coverage is 104.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corline Biomedical AB's current Interest Coverage is No Debt (1), which is 100% below median its own 10-year median of 10,000.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corline Biomedical AB stock overvalued right now?
Corline Biomedical AB (FRA:IZ7) has a current Interest Coverage of No Debt (1). The stock's GF Value™ is €0.45, compared to a current price of €1.55 — trading 243.3% above its estimated fair value. The current Interest Coverage is No Debt (1), which is 100% below median its 10-year median of 10,000.00. Corline Biomedical AB's overall GF Score™ is 43/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Coverage calculated?
Interest Coverage is calculated from a company's financial statements. For Corline Biomedical AB (FRA:IZ7), the current Interest Coverage is No Debt (1) as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corline Biomedical AB (FRA:IZ7) Overvalued in 2026?
Based on GuruFocus' analysis, Corline Biomedical AB stock appears to be overvalued.
The current stock price of €1.55 is trading 243.3% above its estimated GF Value™ of €0.45.
Key valuation signals for FRA:IZ7:
Interest Coverage: No Debt (1) (100% below median its 10-year median of 10,000.00)
GF Value™: €0.45 vs. price of €1.55 (243.3% above fair value)
No single metric tells the full story. See the FRA:IZ7 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corline Biomedical AB offers customers in the medical technology industry and regenerative medicine as well as transplant clinics products to manage immune thrombosis. The company offers a proprietary surface treatment technology, Corline Heparin Surface (CHS), which can be used in combination with all commonly used implant materials such as polymers (plastics) and various metals, but also for equipment where blood circulation occurs outside the body.
43GF Score
Get the complete analysis for FRA:IZ7
Interest Coverage is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:IZ7 has been successfully added to your 
